Trellis Bioscience Inc. said Tuesday its technology will be used in a collaboration with PDL BioPharma Inc. to discover monoclonal antibodies. South San Francisco-based Trellis, a privately held biotech, did not disclose specific financial terms of the deal with Fremont-based PDL BioPharma, (NASDAQ:PDLI) but said PDL BioPharma will pay an upfront fee, milestone payments and royalties.
